Analytical and Bioanalytical Chemistry

, Volume 409, Issue 2, pp 395–410 | Cite as

Glycans and glycoproteins as specific biomarkers for cancer

  • Muchena J. Kailemia
  • Dayoung Park
  • Carlito B. Lebrilla
Review
First Online:
Received:
Revised:
Accepted:
Part of the following topical collections:
  1. Glycomics, Glycoproteomics and Allied Topics

Abstract

Protein glycosylation and other post-translational modifications are involved in potentially all aspects of human growth and development. Defective glycosylation has adverse effects on human physiological conditions and accompanies many chronic and infectious diseases. Altered glycosylation can occur at the onset and/or during tumor progression. Identifying these changes at early disease stages may aid in making decisions regarding treatments, as early intervention can greatly enhance survival. This review highlights some of the efforts being made to identify N- and O-glycosylation profile shifts in cancer using mass spectrometry. The analysis of single or panels of potential glycoprotein cancer markers are covered. Other emerging technologies such as global glycan release and site-specific glycosylation analysis and quantitation are also discussed.

Graphical Abstract

Steps involved in the biomarker discovery

Keywords

Mass spectrometry Cancer Disease biomarker Glycomics Glycoproteomics Site-specific glycosylation 
This is a preview of subscription content, log in to check access.

Notes

Compliance with ethical standards

Conflict of interest

The authors have declared no conflict of interest.

References

  1. 1.
    Jemal A, Bray F, Center MM, Ferlay J, Ward E, Forman D. Global cancer statistics. CA Cancer J Clin. 2011;61(2):69–90.CrossRefGoogle Scholar
  2. 2.
    Ferlay J, Autier P, Boniol M, Heanue M, Colombet M, Boyle P. Estimates of the cancer incidence and mortality in Europe in 2006. Ann Oncol. 2007;18(3):581–92.CrossRefGoogle Scholar
  3. 3.
    Ferlay J, Shin HR, Bray F, Forman D, Mathers C, Parkin DM. Estimates of worldwide burden of cancer in 2008: GLOBOCAN 2008. Int J Cancer. 2010;127(12):2893–917.CrossRefGoogle Scholar
  4. 4.
    Jemal A, Siegel R, Ward E, Hao Y, Xu J, Murray T, et al. Cancer statistics, 2008. CA Cancer J Clin. 2008;58(2):71–96.CrossRefGoogle Scholar
  5. 5.
    Siegel RL, Miller KD, Jemal A. Cancer statistics, 2016. CA Cancer J Clin. 2016;66(1):7–30.CrossRefGoogle Scholar
  6. 6.
    Sawyers CL. The cancer biomarker problem. Nature. 2008;452(7187):548–52.CrossRefGoogle Scholar
  7. 7.
    Kohn EC, Azad N, Annunziata C, Dhamoon AS, Whiteley G. Proteomics as a tool for biomarker discovery. Dis Markers. 2007;23(5/6):411–7.CrossRefGoogle Scholar
  8. 8.
    Diamandis EP, van der Merwe D-E. Plasma protein profiling by mass spectrometry for cancer diagnosis: opportunities and limitations. Clin Cancer Res. 2005;11(3):963–5.Google Scholar
  9. 9.
    Kulasingam V, Diamandis EP. Strategies for discovering novel cancer biomarkers through utilization of emerging technologies. Nat Clin Pract Oncol. 2008;5(10):588–99.CrossRefGoogle Scholar
  10. 10.
    van’t Veer LJ, Dai H, van de Vijver MJ, He YD, Hart AAM, Mao M, et al. Gene expression profiling predicts clinical outcome of breast cancer. Nature. 2002;415(6871):530–6.CrossRefGoogle Scholar
  11. 11.
    Espina V, Woodhouse EC, Wulfkuhle J, Asmussen HD, Petricoin Iii EF, Liotta LA. Protein microarray detection strategies: focus on direct detection technologies. J Immunol Methods. 2004;290(1/2):121–33.CrossRefGoogle Scholar
  12. 12.
    Wulfkuhle JD, Liotta LA, Petricoin EF. Proteomic applications for the early detection of cancer. Nat Rev Cancer. 2003;3(4):267–75.CrossRefGoogle Scholar
  13. 13.
    Nagler RM. Saliva as a tool for oral cancer diagnosis and prognosis. Oral Oncol. 2009;45(12):1006–10.CrossRefGoogle Scholar
  14. 14.
    Laxman B, Morris DS, Yu J, Siddiqui J, Cao J, Mehra R, et al. A first-generation multiplex biomarker analysis of urine for the early detection of prostate cancer. Cancer Res. 2008;68(3):645–9.CrossRefGoogle Scholar
  15. 15.
    Alexander H, Stegner AL, Wagner-Mann C, Du Bois GC, Alexander S, Sauter ER. Proteomic analysis to identify breast cancer biomarkers in nipple aspirate fluid. Clin Cancer Res. 2004;10(22):7500–10.CrossRefGoogle Scholar
  16. 16.
    Teng P-N, Bateman NW, Hood BL, Conrads TP. Advances in proximal fluid proteomics for disease biomarker discovery. J Proteome Res. 2010;9(12):6091–100.CrossRefGoogle Scholar
  17. 17.
    Hanash SM, Pitteri SJ, Faca VM. Mining the plasma proteome for cancer biomarkers. Nature. 2008;452(7187):571–9.CrossRefGoogle Scholar
  18. 18.
    Hassanein M, Callison JC, Callaway-Lane C, Aldrich MC, Grogan EL, Massion PP. The state of molecular biomarkers for the early detection of lung cancer. Cancer Prev Res. 2012;5(8):992–1006.CrossRefGoogle Scholar
  19. 19.
    Polanski M, Anderson NL. A list of candidate cancer biomarkers for targeted proteomics. Biomarker Insights. 2006;1:1.Google Scholar
  20. 20.
    Chen X, Shan Q, Jiang L, Zhu B, Xi X. Quantitative proteomic analysis by iTRAQ for identification of candidate biomarkers in plasma from acute respiratory distress syndrome patients. Biochem Biophys Res Commun. 2013;441(1):1–6.CrossRefGoogle Scholar
  21. 21.
    Lam YW, Mobley JA, Evans JE, Carmody JF, Ho SM. Mass profiling-directed isolation and identification of a stage-specific serologic protein biomarker of advanced prostate cancer. Proteomics. 2005;5(11):2927–38.CrossRefGoogle Scholar
  22. 22.
    Palmblad M, Tiss A, Cramer R. Mass spectrometry in clinical proteomics—from the present to the future. Proteom Clin Appl. 2009;3(1):6–17.CrossRefGoogle Scholar
  23. 23.
    Miller RA, Spellman DS. Mass spectrometry-based biomarkers in drug development. In: Woods AG, Darie CC (Ed.) Advancements of mass spectrometry in biomedical research, vol 806, pp 341–359. Advances in Experimental Medicine and Biology. Switzerland: Springer International Publishing; 2014.Google Scholar
  24. 24.
    Pusch W, Flocco MT, Leung SM, Thiele H, Kostrzewa M. Mass spectrometry-based clinical proteomics. Pharmacogenomics. 2003;4(4):463–76.CrossRefGoogle Scholar
  25. 25.
    Zhang Y, Jiao J, Yang P, Lu H. Mass spectrometry-based N-glycoproteomics for cancer biomarker discovery. Clin Proteom. 2014;11(1):18.CrossRefGoogle Scholar
  26. 26.
    Jimenez CR, Verheul HMW. Mass spectrometry-based proteomics: from cancer biology to protein biomarkers, drug targets, and clinical applications. Am Soc Clinl Oncol educational book/ASCO Am Soc Clin Oncol Meeting. e504–510. 2014.Google Scholar
  27. 27.
    Yin H, Lin Z, Nie S, Wu J, Tan Z, Zhu J, et al. Mass-selected site-specific core-fucosylation of ceruloplasmin in alcohol-related hepatocellular carcinoma. J Proteome Res. 2014;13(6):2887–96.CrossRefGoogle Scholar
  28. 28.
    Griffiths WJ, Wang Y. Mass spectrometry: from proteomics to metabolomics and lipidomics. Chem Soc Rev. 2009;38(7):1882–96.CrossRefGoogle Scholar
  29. 29.
    Ly M, Laremore TN, Linhardt RJ. Proteoglycomics: recent progress and future challenges. OMICS J Integrative Biol. 2010;14(4):389–99.CrossRefGoogle Scholar
  30. 30.
    Wuhrer M, Catalina MI, Deelder AM, Hokke CH. Glycoproteomics based on tandem mass spectrometry of glycopeptides. J Chromatogr B. 2007;849(1):115–28.CrossRefGoogle Scholar
  31. 31.
    Zaia J. Mass spectrometry and the emerging field of glycomics. Chem Biol. 2008;15(9):881–92.CrossRefGoogle Scholar
  32. 32.
    Hua S, Lebrilla C, An HJ. Application of nano-LC-based glycomics towards biomarker discovery. Bioanalysis. 2011;3(22):2573–85.CrossRefGoogle Scholar
  33. 33.
    Alley WR, Madera M, Mechref Y, Novotny MV. Chip-based reversed-phase liquid chromatography-mass spectrometry of permethylated N-linked glycans: a potential methodology for cancer-biomarker discovery. Anal Chem. 2010;82(12):5095–106.CrossRefGoogle Scholar
  34. 34.
    Eng JK, McCormack AL, Yates JR. An approach to correlate tandem mass spectral data of peptides with amino acid sequences in a protein database. J Am Soc Mass Spectrom. 1994;5(11):976–89.CrossRefGoogle Scholar
  35. 35.
    Kronewitter SR, De Leoz MLA, Strum JS, An HJ, Dimapasoc LM, Guerrero A, et al. The glycolyzer: automated glycan annotation software for high performance mass spectrometry and its application to ovarian cancer glycan biomarker discovery. Proteomics. 2012;12(15/16):2523–38.CrossRefGoogle Scholar
  36. 36.
    Ludwig JA, Weinstein JN. Biomarkers in cancer staging, prognosis, and treatment selection. Nat Rev Cancer. 2005;5(11):845–56.CrossRefGoogle Scholar
  37. 37.
    Yin BWT, Lloyd KO. Molecular Cloning of the CA125 Ovarian Cancer Antigen: identification as a new mucin, MUC16. J Biol Chem. 2001;276(29):27371–5.CrossRefGoogle Scholar
  38. 38.
    Jacobs I, Bast RC. The CA 125 tumor-associated antigen: a review of the literature. Hum Reprod. 1989;4(1):1–12.Google Scholar
  39. 39.
    Miralles C, Orea M, España P, Provencio M, Sánchez A, Cantos B, et al. Cancer antigen 125 associated with multiple benign and malignant pathologies. Ann Surg Oncol. 2003;10(2):150–4.CrossRefGoogle Scholar
  40. 40.
    Adamczyk B, Tharmalingam T, Rudd PM. Glycans as cancer biomarkers. Biochim Biophys Acta - General Subjects. 2012;1820(9):1347–53.CrossRefGoogle Scholar
  41. 41.
    Duffy M, Shering S, Sherry F, McDermott E, O'higgins N. CA 15-3: a prognostic marker in breast cancer. Int J Biol Markers. 1999;15(4):330–3.Google Scholar
  42. 42.
    Drake RR, Jones EE, Powers TW, Nyalwidhe JO. Chapter 10-altered glycosylation in prostate cancer. Adv Cancer Res. 2015;126:345–82.CrossRefGoogle Scholar
  43. 43.
    Catalona W, Richie J, Ahmann F, Hudson M, Scardino P, Flanigan R, et al. Comparison of digital rectal examination and serum prostate specific antigen in the early detection of prostate cancer: results of a multicenter clinical trial of 6,630 men. J Urol. 1994;151(5):1283–90.Google Scholar
  44. 44.
    Hammarström S. The carcinoembryonic antigen (CEA) family: structures, suggested functions, and expression in normal and malignant tissues. Semin Cancer Biol. 1999;9(2):67–81.CrossRefGoogle Scholar
  45. 45.
    Benchimol S, Fuks A, Jothy S, Beauchemin N, Shirota K, Stanners CP. Carcinoembryonic antigen, a human tumor marker, functions as an intercellular adhesion molecule. Cell. 1989;57(2):327–34.CrossRefGoogle Scholar
  46. 46.
    Moertel CG, Fleming TR, Macdonald JS, Haller DG, Laurie JA, Tangen C. An evaluation of the carcinoembryonic antigen (CEA) test for monitoring patients with resected colon cancer. JAMA. 1993;270(8):943–7.CrossRefGoogle Scholar
  47. 47.
    Thompson S, Turner G. Elevated levels of abnormally-fucosylated haptoglobins in cancer sera. Br J Cancer. 1987;56(5):605.CrossRefGoogle Scholar
  48. 48.
    Okuyama N, Ide Y, Nakano M, Nakagawa T, Yamanaka K, Moriwaki K, et al. Fucosylated haptoglobin is a novel marker for pancreatic cancer: a detailed analysis of the oligosaccharide structure and a possible mechanism for fucosylation. Int J Cancer. 2006;118(11):2803–8.CrossRefGoogle Scholar
  49. 49.
    Miyoshi E, Nakano M. Fucosylated haptoglobin is a novel marker for pancreatic cancer: detailed analyses of oligosaccharide structures. Proteomics. 2008;8(16):3257–62.CrossRefGoogle Scholar
  50. 50.
    Zhao C, Annamalai L, Guo C, Kothandaraman N, Koh SCL, Zhang H, et al. Circulating haptoglobin is an independent prognostic factor in the sera of patients with epithelial ovarian cancer. Neoplasia (New York, NY). 2007;9(1):1–7.CrossRefGoogle Scholar
  51. 51.
    Ahmed N, Barker G, Oliva KT, Hoffmann P, Riley C, Reeve S, et al. Proteomic-based identification of haptoglobin-1 precursor as a novel circulating biomarker of ovarian cancer. Br J Cancer. 2004;91(1):129–40.CrossRefGoogle Scholar
  52. 52.
    Huang HL, Stasyk T, Morandell S, Dieplinger H, Falkensammer G, Griesmacher A, et al. Biomarker discovery in breast cancer serum using 2-D differential gel electrophoresis/MALDI-TOF/TOF and data validation by routine clinical assays. Electrophoresis. 2006;27(8):1641–50.CrossRefGoogle Scholar
  53. 53.
    Ralhan R, DeSouza LV, Matta A, Tripathi SC, Ghanny S, Gupta SD, et al. Discovery and verification of head-and-neck cancer biomarkers by differential protein expression analysis using iTRAQ labeling, multidimensional liquid chromatography, and tandem mass spectrometry. Mol Cell Proteom. 2008;7(6):1162–73.CrossRefGoogle Scholar
  54. 54.
    Patz EF, Campa MJ, Gottlin EB, Kusmartseva I, Guan XR, Herndon JE. Panel of serum biomarkers for the diagnosis of lung cancer. J Clin Oncol. 2007;25(35):5578–83.CrossRefGoogle Scholar
  55. 55.
    Drake RR, Schwegler EE, Malik G, Diaz J, Block T, Mehta A, et al. Lectin capture strategies combined with mass spectrometry for the discovery of serum glycoprotein biomarkers. Mol Cell Proteom. 2006;5(10):1957–67.CrossRefGoogle Scholar
  56. 56.
    Zhao J, Simeone DM, Heidt D, Anderson MA, Lubman DM. Comparative serum glycoproteomics using lectin selected sialic acid glycoproteins with mass spectrometric analysis: application to pancreatic cancer serum. J Proteome Res. 2006;5(7):1792–802.CrossRefGoogle Scholar
  57. 57.
    Kaji H, Saito H, Yamauchi Y, Shinkawa T, Taoka M, Hirabayashi J, et al. Lectin affinity capture, isotope-coded tagging, and mass spectrometry to identify N-linked glycoproteins. Nat Biotech. 2003;21(6):667–72.CrossRefGoogle Scholar
  58. 58.
    Wu J, Xie X, Liu Y, He J, Benitez R, Buckanovich RJ, et al. Identification and confirmation of differentially expressed fucosylated glycoproteins in the serum of ovarian cancer patients using a lectin array and LC-MS/MS. J Proteome Res. 2012;11(9):4541–52.CrossRefGoogle Scholar
  59. 59.
    Alvarez-Manilla G, Warren NL, Atwood III J, Orlando R, Dalton S, Pierce M. Glycoproteomic analysis of embryonic stem cells: identification of potential glycobiomarkers using lectin affinity chromatography of glycopeptides. J Proteome Res. 2010;9(5):2062–75.CrossRefGoogle Scholar
  60. 60.
    Kuno A, Kato Y, Matsuda A, Kaneko MK, Ito H, Amano K, et al. Focused differential glycan analysis with the platform antibody-assisted lectin profiling for glycan-related biomarker verification. Mol Cell Proteom. 2009;8(1):99–108.CrossRefGoogle Scholar
  61. 61.
    Li Y, Wen T, Zhu M, Li L, Wei J, Wu X, et al. Glycoproteomic analysis of tissues from patients with colon cancer using lectin microarrays and nanoLC-MS/MS. Mol Biosyst. 2013;9(7):1877–87.CrossRefGoogle Scholar
  62. 62.
    Dennis JW, Laferte S, Waghorne C, Breitman ML, Kerbel RS. Beta 1-6 branching of Asn-linked oligosaccharides is directly associated with metastasis. Science. 1987;236(4801):582–5.CrossRefGoogle Scholar
  63. 63.
    Ihara S, Miyoshi E, Ko JH, Murata K, Nakahara S, Honke K, et al. Prometastatic effect of N-acetylglucosaminyltransferase V is due to modification and stabilization of active matriptase by adding β1–6 GlcNAc branching. J Biol Chem. 2002;277(19):16960–7.CrossRefGoogle Scholar
  64. 64.
    Buckhaults P, Chen L, Fregien N, Pierce M. Transcriptional regulation of N-acetylglucosaminyltransferase V by the src oncogene. J Biol Chem. 1997;272(31):19575–81.CrossRefGoogle Scholar
  65. 65.
    Abbott KL, Aoki K, Lim J-M, Porterfield M, Johnson R, O'Regan RM, et al. Targeted glycoproteomic identification of biomarkers for human breast carcinoma. J Proteome Res. 2008;7(4):1470–80.CrossRefGoogle Scholar
  66. 66.
    Thompson A, Schäfer J, Kuhn K, Kienle S, Schwarz J, Schmidt G, et al. Tandem mass tags: a novel quantification strategy for comparative analysis of complex protein mixtures by MS/MS. Anal Chem. 2003;75(8):1895–904.CrossRefGoogle Scholar
  67. 67.
    Nie S, Lo A, Wu J, Zhu J, Tan Z, Simeone DM, et al. Glycoprotein biomarker panel for pancreatic cancer discovered by quantitative proteomics analysis. J Proteome Res. 2014;13(4):1873–84.CrossRefGoogle Scholar
  68. 68.
    Mann M, Jensen ON. Proteomic analysis of post-translational modifications. Nat Biotech. 2003;21(3):255–61.CrossRefGoogle Scholar
  69. 69.
    Pagel O, Loroch S, Sickmann A, Zahedi RP. Current strategies and findings in clinically relevant post-translational modification-specific proteomics. Expert Rev Proteom. 2015;12(3):235–53.CrossRefGoogle Scholar
  70. 70.
    Christiansen MN, Chik J, Lee L, Anugraham M, Abrahams JL, Packer NH. Cell surface protein glycosylation in cancer. Proteomics. 2014;14(4/5):525–46.CrossRefGoogle Scholar
  71. 71.
    Holst S, Wuhrer M, Rombouts Y (2015) Chapter 6 – Glycosylation characteristics of colorectal cancer. In: Richard RD, Lauren EB (Eds.) Advances in Cancer Research, vol 126, pp 203–256. Academic Press.Google Scholar
  72. 72.
    Walsh G, Jefferis R. Post-translational modifications in the context of therapeutic proteins. Nat Biotech. 2006;24(10):1241–52.CrossRefGoogle Scholar
  73. 73.
    An HJ, Froehlich JW, Lebrilla CB. Determination of glycosylation sites and site-specific heterogeneity in glycoproteins. Curr Opin Chem Biol. 2009;13(4):421–6.CrossRefGoogle Scholar
  74. 74.
    Shriver Z, Raguram S, Sasisekharan R. Glycomics: a pathway to a class of new and improved therapeutics. Nat Rev Drug Discov. 2004;3(10):863–73.CrossRefGoogle Scholar
  75. 75.
    Dube DH, Bertozzi CR. Glycans in cancer and inflammation—potential for therapeutics and diagnostics. Nat Rev Drug Discov. 2005;4(6):477–88.CrossRefGoogle Scholar
  76. 76.
    Reis CA, Osorio H, Silva L, Gomes C, David L. Alterations in glycosylation as biomarkers for cancer detection. J Clin Pathol. 2010;63(4):322–9.CrossRefGoogle Scholar
  77. 77.
    Varki A, Kannagi R, Toole BP. Glycosylation changes in cancer. 2009.Google Scholar
  78. 78.
    An HJ, Kronewitter SR, de Leoz MLA, Lebrilla CB. Glycomics and disease markers. Curr Opin Chem Biol. 2009;13(5/6):601–7.CrossRefGoogle Scholar
  79. 79.
    Guo H, Abbott KL (2015) Chapter 8 – functional impact of tumor-specific N-linked glycan changes in breast and ovarian cancers. In: Richard RD, Lauren EB (Eds.) Advances in Cancer Research, vol 126, pp 281–303. Academic Press.Google Scholar
  80. 80.
    Drake PM, Cho W, Li B, Prakobphol A, Johansen E, Anderson NL, et al. Sweetening the pot: adding glycosylation to the biomarker discovery equation. Clin Chem. 2010;56(2):223–36.CrossRefGoogle Scholar
  81. 81.
    Pinho SS, Reis CA. Glycosylation in cancer: mechanisms and clinical implications. Nat Rev Cancer. 2015;15:540–55.Google Scholar
  82. 82.
    de Leoz MLA, Young LJT, An HJ, Kronewitter SR, Kim J, Miyamoto S, et al. High-mannose glycans are elevated during breast cancer progression. Mol Cell Proteom. 2011;10(1).Google Scholar
  83. 83.
    Kailemia MJ, Ruhaak LR, Lebrilla CB, Amster IJ. Oligosaccharide analysis by mass spectrometry: a review of recent developments. Anal Chem. 2013;86(1):196–212.CrossRefGoogle Scholar
  84. 84.
    Ruhaak LR, Miyamoto S, Lebrilla CB. Developments in the identification of glycan biomarkers for the detection of cancer. Mol Cell Proteom. 2013;12(4):846–55.CrossRefGoogle Scholar
  85. 85.
    Budnik BA, Lee RS, Steen JAJ. Global methods for protein glycosylation analysis by mass spectrometry. Biochim Biophys Acta. 2006;1764(12):1870–80.CrossRefGoogle Scholar
  86. 86.
    An HJ, Lebrilla CB (2010) A glycomics approach to the discovery of potential cancer biomarkers. In: Functional glycomics, 199–213. Springer.Google Scholar
  87. 87.
    JooáAn H. The prospects of glycan biomarkers for the diagnosis of diseases. Mol Biosyst. 2009;5(1):17–20.CrossRefGoogle Scholar
  88. 88.
    An HJ, Miyamoto S, Lancaster KS, Kirmiz C, Li B, Lam KS, et al. Profiling of glycans in serum for the discovery of potential biomarkers for ovarian cancer. J Proteome Res. 2006;5(7):1626–35.CrossRefGoogle Scholar
  89. 89.
    Bharti A, Ma PC, Maulik G, Singh R, Khan E, Skarin AT, et al. Haptoglobin α-subunit and hepatocyte growth factor can potentially serve as serum tumor biomarkers in small-cell lung cancer. Anticancer Res. 2004;24(2C):1031–8.Google Scholar
  90. 90.
    Bones J, Mittermayr S, O'Donoghue N, Guttman A, Rudd PM. Ultra performance liquid chromatographic profiling of serum N-glycans for fast and efficient identification of cancer associated alterations in glycosylation. Anal Chem. 2010;82(24):10208–15.CrossRefGoogle Scholar
  91. 91.
    Wada Y, Azadi P, Costello CE, Dell A, Dwek RA, Geyer H, et al. Comparison of the methods for profiling glycoprotein glycans—HUPO Human Disease Glycomics/Proteome Initiative multi-institutional study. Glycobiology. 2007;17(4):411–22.CrossRefGoogle Scholar
  92. 92.
    Ressom HW, Varghese RS, Goldman L, An Y, Loffredo CA, Abdel-Hamid M, et al. Analysis of MALDI-TOF mass spectrometry data for discovery of peptide and glycan biomarkers of hepatocellular carcinoma. J Proteome Res. 2008;7(2):603–10.CrossRefGoogle Scholar
  93. 93.
    Rodrigo MAM, Zitka O, Krizkova S, Moulick A, Adam V, Kizek R. MALDI-TOF MS as evolving cancer diagnostic tool: a review. J Pharm Biomed Anal. 2014;95:245–55.CrossRefGoogle Scholar
  94. 94.
    Powers TW, Neely BA, Shao Y, Tang H, Troyer DA, Mehta AS, et al. MALDI imaging mass spectrometry profiling of N-glycans in formalin-fixed paraffin embedded clinical tissue blocks and tissue microarrays. PLoS One. 2014;9(9).Google Scholar
  95. 95.
    Kyselova Z, Mechref Y, Al Bataineh MM, Dobrolecki LE, Hickey RJ, Vinson J, et al. Alterations in the serum glycome due to metastatic prostate cancer. J Proteome Res. 2007;6(5):1822–32.CrossRefGoogle Scholar
  96. 96.
    Kyselova Z, Mechref Y, Kang P, Goetz JA, Dobrolecki LE, Sledge GW, et al. Breast cancer diagnosis and prognosis through quantitative measurements of serum glycan profiles. Clin Chem. 2008;54(7):1166–75.CrossRefGoogle Scholar
  97. 97.
    Balog CIA, Stavenhagen K, Fung WLJ, Koeleman CA, McDonnell LA, Verhoeven A, et al. N-glycosylation of colorectal cancer tissues. Mol Cell Proteom. 2012;11(9):571–85.CrossRefGoogle Scholar
  98. 98.
    de Leoz MLA, An HJ, Kronewitter S, Kim J, Beecroft S, Vinall R, et al. Glycomic approach for potential biomarkers on prostate cancer: Profiling of N-linked glycans in human sera and pRNS cell lines. Dis Markers. 2008;25(4/5):243–58.CrossRefGoogle Scholar
  99. 99.
    Hecht ES, Scholl EH, Walker SH, Taylor AD, Cliby WA, Motsinger-Reif AA, et al. Relative quantification and higher-order modeling of the plasma glycan cancer burden ratio in ovarian cancer case-control samples. J Proteome Res. 2015;14(10):4394–401.CrossRefGoogle Scholar
  100. 100.
    Kirmiz C, Li B, An HJ, Clowers BH, Chew HK, Lam KS, et al. A serum glycomics approach to breast cancer biomarkers. Mol Cell Proteom. 2007;6(1):43–55.CrossRefGoogle Scholar
  101. 101.
    Alley WR, Vasseur JA, Goetz JA, Svoboda M, Mann BF, Matei DE, et al. N-linked glycan structures and their expressions change in the blood sera of ovarian cancer patients. J Proteome Res. 2012;11(4):2282–300.CrossRefGoogle Scholar
  102. 102.
    Saldova R, Royle L, Radcliffe CM, Abd Hamid UM, Evans R, Arnold JN, et al. Ovarian cancer is associated with changes in glycosylation in both acute-phase proteins and IgG. Glycobiology. 2007;17(12):1344–56.CrossRefGoogle Scholar
  103. 103.
    Kanoh Y, Mashiko T, Danbara M, Takayama Y, Ohtani S, Imasaki T, et al. Analysis of the Oligosaccharide chain of human serum immunoglobulin G in patients with localized or metastatic cancer. Oncology. 2004;66(5):365–70.CrossRefGoogle Scholar
  104. 104.
    Ruhaak LR, Stroble C, Dai J, Barnett MJ, Taguchi A, Goodman GE, et al. Serum glycans as risk markers for non-small cell lung cancer. Cancer Prev Res. 2016. doi: 10.1158/1940-6207.capr-15-0033.Google Scholar
  105. 105.
    Hua S, An HJ, Ozcan S, Ro GS, Soares S, DeVere-White R, et al. Comprehensive native glycan profiling with isomer separation and quantitation for the discovery of cancer biomarkers. Analyst. 2011;136(18):3663–71.CrossRefGoogle Scholar
  106. 106.
    Ruhaak LR, Deelder A, Wuhrer M. Oligosaccharide analysis by graphitized carbon liquid chromatography-mass spectrometry. Anal Bioanal Chem. 2009;394(1):163–74.CrossRefGoogle Scholar
  107. 107.
    Stavenhagen K, Kolarich D, Wuhrer M. Clinical glycomics employing graphitized carbon liquid chromatography-mass spectrometry. Chromatographia. 2014;78(5):307–20.Google Scholar
  108. 108.
    Chu CS, Niñonuevo MR, Clowers BH, Perkins PD, An HJ, Yin H, et al. Profile of native N-linked glycan structures from human serum using high performance liquid chromatography on a microfluidic chip and time-of-flight mass spectrometry. Proteomics. 2009;9(7):1939–51.CrossRefGoogle Scholar
  109. 109.
    Song T, Aldredge D, Lebrilla CB. A method for in-depth structural annotation of human serum glycans that yields biological variations. Anal Chem. 2015;87(15):7754–62.CrossRefGoogle Scholar
  110. 110.
    Ruhaak LR, Barkauskas DA, Torres J, Cooke CL, Wu LD, Stroble C, et al. The serum immunoglobulin G glycosylation signature of gastric cancer. EuPA Open Proteom. 2015;6:1–9.CrossRefGoogle Scholar
  111. 111.
    Strum JS, Nwosu CC, Hua S, Kronewitter SR, Seipert RR, Bachelor RJ, et al. Automated Assignments of N- and O-site specific glycosylation with extensive glycan heterogeneity of glycoprotein mixtures. Anal Chem. 2013;85(12):5666–75.CrossRefGoogle Scholar
  112. 112.
    Nwosu CC, Seipert RR, Strum JS, Hua SS, An HJ, Zivkovic AM, et al. Simultaneous and extensive site-specific N- and O-glycosylation analysis in protein mixtures. J Proteome Res. 2011;10(5):2612–24.CrossRefGoogle Scholar
  113. 113.
    Ueda K, Takami S, Saichi N, Daigo Y, Ishikawa N, Kohno N, et al. Development of serum glycoproteomic profiling technique; simultaneous identification of glycosylation sites and site-specific quantification of glycan structure changes. Mol Cell Proteom. 2010;9(9):1819–28.CrossRefGoogle Scholar
  114. 114.
    Ueda K. Glycoproteomic strategies: From discovery to clinical application of cancer carbohydrate biomarkers. Proteom Clin App. 2013;7(9/10):607–17.Google Scholar
  115. 115.
    Bern M, Kil YJ, Becker C. Byonic: advanced peptide and protein identification software. Curr Protoc Bioinform. 2012;40:13.20.11–13.20.14.Google Scholar
  116. 116.
    Ozohanics O, Krenyacz J, Ludányi K, Pollreisz F, Vékey K, Drahos L. GlycoMiner: a new software tool to elucidate glycopeptide composition. Rapid Commun Mass Spectrom. 2008;22(20):3245–54.CrossRefGoogle Scholar
  117. 117.
    He L, Xin L, Shan B, Lajoie GA, Ma B. GlycoMaster DB: Software to assist the automated identification of N-linked glycopeptides by tandem mass spectrometry. J Proteome Res. 2014;13(9):3881–95.CrossRefGoogle Scholar
  118. 118.
    Mayampurath A, Yu C-Y, Song E, Balan J, Mechref Y, Tang H. Computational framework for identification of intact glycopeptides in complex samples. Anal Chem. 2014;86(1):453–63.CrossRefGoogle Scholar
  119. 119.
    Mayampurath AM, Wu Y, Segu ZM, Mechref Y, Tang H. Improving confidence in detection and characterization of protein N‐glycosylation sites and microheterogeneity. Rapid Commun Mass Spectrom. 2011;25(14):2007–19.CrossRefGoogle Scholar
  120. 120.
    Khatri K, Staples GO, Leymarie N, Leon DR, Turiák L, Huang Y, et al. Confident assignment of site-specific glycosylation in complex glycoproteins in a single step. J Proteome Res. 2014;13(10):4347–55.CrossRefGoogle Scholar
  121. 121.
    Go EP, Rebecchi KR, Dalpathado DS, Bandu ML, Zhang Y, Desaire H. GlycoPep DB: a tool for glycopeptide analysis using a “Smart Search”. Anal Chem. 2007;79(4):1708–13.CrossRefGoogle Scholar
  122. 122.
    Woodin CL, Maxon M, Desaire H. Software for automated interpretation of mass spectrometry data from glycans and glycopeptides. Analyst. 2013;138(10):2793–803.CrossRefGoogle Scholar
  123. 123.
    Reid GE, Stephenson JL, McLuckey SA. Tandem mass spectrometry of ribonuclease A and B: N-linked glycosylation site analysis of whole protein ions. Anal Chem. 2002;74(3):577–83.CrossRefGoogle Scholar
  124. 124.
    Siuti N, Kelleher NL. Decoding protein modifications using top-down mass spectrometry. Nat Methods. 2007;4(10):817–21.CrossRefGoogle Scholar
  125. 125.
    Ito S, Hayama K, Hirabayashi J (2009) Enrichment strategies for glycopeptides. In: Packer N, Karlsson N (Eds.) Glycomics, vol 534, pp 194–203. Methods in Molecular Biology. Humana Press.Google Scholar
  126. 126.
    Wuhrer M, Deelder AM, Hokke CH. Protein glycosylation analysis by liquid chromatography–mass spectrometry. J Chromatogr B. 2005;825(2):124–33.CrossRefGoogle Scholar
  127. 127.
    Zhu Z, Go EP, Desaire H. Absolute quantitation of glycosylation site occupancy using isotopically labeled standards and LC-MS. J Am Soc Mass Spectrom. 2014;25(6):1012–7.CrossRefGoogle Scholar
  128. 128.
    Dalpathado DS, Desaire H. Glycopeptide analysis by mass spectrometry. Analyst. 2008;133(6):731–8.CrossRefGoogle Scholar
  129. 129.
    Gbormittah FO, Bones J, Hincapie M, Tousi F, Hancock WS, Iliopoulos O. Clusterin glycopeptide variant characterization reveals significant site-specific glycan changes in the plasma of clear cell renal cell carcinoma. J Proteome Res. 2015;14(6):2425–36.CrossRefGoogle Scholar
  130. 130.
    Tan Z, Yin H, Nie S, Lin Z, Zhu J, Ruffin MT, et al. Large-scale identification of core-fucosylated glycopeptide sites in pancreatic cancer serum using mass spectrometry. J Proteome Res. 2015;14(4):1968–78.CrossRefGoogle Scholar
  131. 131.
    Lin Z, Yin H, Lo A, Ruffin MT, Anderson MA, Simeone DM, et al. Label-free relative quantification of α-2-macroglobulin site-specific core-fucosylation in pancreatic cancer by LC-MS/MS. Electrophoresis. 2014;35(15):2108–15.Google Scholar
  132. 132.
    Saldova R, Fan Y, Fitzpatrick JM, Watson RWG, Rudd PM. Core fucosylation and α2-3 sialylation in serum N-glycome is significantly increased in prostate cancer comparing to benign prostate hyperplasia. Glycobiology. 2011;21(2):195–205.CrossRefGoogle Scholar
  133. 133.
    Miyoshi E, Moriwaki K, Nakagawa T. Biological function of fucosylation in cancer biology. J Biochem. 2008;143(6):725–9.CrossRefGoogle Scholar
  134. 134.
    Ruhaak LR, Lebrilla C. Applications of multiple reaction monitoring to clinical glycomics. Chromatographia. 2015;78(5/6):335–42.CrossRefGoogle Scholar
  135. 135.
    Picotti P, Aebersold R. Selected reaction monitoring-based proteomics: workflows, potential, pitfalls and future directions. Nat Meth. 2012;9(6):555–66.CrossRefGoogle Scholar
  136. 136.
    Song E, Pyreddy S, Mechref Y. Quantification of glycopeptides by multiple reaction monitoring liquid chromatography/tandem mass spectrometry. Rapid Commun Mass Spectrom. 2012;26(17):1941–54.CrossRefGoogle Scholar
  137. 137.
    Hong Q, Lebrilla CB, Miyamoto S, Ruhaak LR. Absolute quantitation of immunoglobulin G and its glycoforms using multiple reaction monitoring. Anal Chem. 2013;85(18):8585–93.CrossRefGoogle Scholar
  138. 138.
    Sanda M, Pompach P, Brnakova Z, Wu J, Makambi K, Goldman R. Quantitative liquid chromatography-mass spectrometry-multiple reaction monitoring (LC-MS-MRM) analysis of site-specific glycoforms of haptoglobin in liver disease. Mol Cell Proteom. 2013;12(5):1294–305.CrossRefGoogle Scholar
  139. 139.
    Yuan W, Sanda M, Wu J, Koomen J, Goldman R. Quantitative analysis of immunoglobulin subclasses and subclass specific glycosylation by LC-MS-MRM in liver disease. J Proteom. 2015;116:24–33.CrossRefGoogle Scholar
  140. 140.
    Anderson NL, Anderson NG, Haines LR, Hardie DB, Olafson RW, Pearson TW. Mass spectrometric quantitation of peptides and proteins using stable isotope standards and capture by anti-peptide antibodies (SISCAPA). J Proteome Res. 2004;3(2):235–44.CrossRefGoogle Scholar
  141. 141.
    Ahn YH, Lee JY, Lee JY, Kim Y-S, Ko JH, Yoo JS. Quantitative analysis of an aberrant glycoform of TIMP1 from colon cancer serum by L-PHA-enrichment and SISCAPA with MRM mass spectrometry. J Proteome Res. 2009;8(9):4216–24.CrossRefGoogle Scholar
  142. 142.
    Hong Q, Ruhaak LR, Stroble C, Parker E, Huang J, Maverakis E, et al. A method for comprehensive glycosite-mapping and direct quantitation of serum glycoproteins. J Proteome Res. 2015;14(12):5179–92.CrossRefGoogle Scholar
  143. 143.
    Ruhaak LR, Kim K, Stroble C, Taylor SL, Hong Q, Miyamoto S, et al. Protein-specific differential glycosylation of immunoglobulins in serum of ovarian cancer patients. J Proteome Res. 2016;15(3):1002–10.CrossRefGoogle Scholar

Copyright information

© Springer-Verlag Berlin Heidelberg 2016

Authors and Affiliations

  • Muchena J. Kailemia
    • 1
  • Dayoung Park
    • 1
  • Carlito B. Lebrilla
    • 1
  1. 1.Department of ChemistryUniversity of CaliforniaDavisUSA

Personalised recommendations